A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Recruiting · Phase 3 · NCT06338995
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
At a glance
- Research payments reported, 2025
- $452,488
- U.S. investigators named
- 19
- Sites paid
- 20
- Planned or actual enrollment
- 510
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3650150 (drug), Placebo (drug), Standard therapy for INCS (drug)
- Dates
- Started 2024-04-29; completion 2028-03
- Results posted
- Not yet
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $452,488 in research payments for this study in 2025 (21 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Do Yeon Cho ENT (Otolaryngology) · Birmingham, AL
- Weily Soong, M.D. Specialist · Birmingham, AL
- Naveen D. Bhandarkar, M.D. ENT (Otolaryngology) · Orange, CA
- Steven E. Davis, M.D. ENT (Otolaryngology) · Torrance, CA
- Randall A. Ow ENT (Otolaryngology) · Loomis, CA
- Bryan M. Davis, M.D. ENT (Otolaryngology) · Colorado Springs, CO
- Seong H. Cho, M.D. Allergy & Immunology · Tampa, FL
- Kirk V. Shepard II, MD, MS Allergy & Immunology · Chicago, IL
- James L. Connolly, M.D. Facial Plastic Surgery · Mandeville, LA
- Stella J. Lee, MD Hand Surgery · Newburyport, MA
- Sudhir Sekhsaria, MD Allergy & Immunology · White Marsh, MD
- Neetu Talreja, MD Hospitalist · Detroit, MI
- H J. Wedner, MD Allergy & Immunology · Saint Louis, MO
- Stacey L. Silvers, M.D. Facial Plastic Surgery · New York, NY
- Sei Y. Chung, M.D. ENT (Otolaryngology) · Dallas, TX
- Dale R. Ehmer JR., M.D. ENT (Otolaryngology) · Frisco, TX
- Amber Luong, M.D., PH.D ENT (Otolaryngology) · Houston, TX
- Jeffery S. Rosenbloom, MD ENT (Otolaryngology) · San Antonio, TX
- David M. Poetker, MD ENT (Otolaryngology) · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Berkson Medical LLC $64,473
- Alamo Ent Associates $46,365
- University of Alabama Hospital, AL $40,985
- Treasure Valley Medical Research $39,151
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $36,230
- Medical College of Wisconsin Inc $34,565
- Davinci Research LLC $33,731
- University of Texas Health $29,853
- Biopharma Clinical Research Services LLC $21,465
- The University of Texas $20,533
- Brigham and Women's Hospital, MA $16,031
- Colorado Otolaryngology Associates DBA Colorado Ent and Allergy $14,258
- Washington University $12,434
- National Institute of Clinical Research $12,000
- Madison Ent and Facial Plastic Surgery $10,207
- Chicago Ent Research LLC $7,083
- Uci Health-Orange, CA $4,750
- Chesapeake Clinical Research $4,250
- Clinical Research Ctr of Alabama, LLC $4,000
- Univ of South Florida Rsrch Foundation $125
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.